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Abstract
Background: Anxiety is common in autistic adults and significantly limits everyday opportunities and quality of life.
Evidence-based psychological therapies offered by mental health services often fail to meet the needs of autistic
adults. The development of appropriate treatments for mental health conditions and, in particular, anxiety has been
identified as a key priority by the autism community. The Personalised Anxiety Treatment–Autism (PAT-A©) trial
aims to address this need by investigating the feasibility and acceptability of delivering an individualised
psychological treatment for anxiety experienced by autistic adults.
Methods/design: This is a pilot randomised controlled feasibility trial. Up to 40 autistic adults with clinically
diagnosed anxiety will be randomised into one of two groups (either the PAT-A© intervention or Current Clinical
Services Plus two emotional literacy skills sessions). Before randomisation, participants will receive a detailed clinical
assessment to inform formulation and guide anxiety treatment. As part of the baseline assessment participants will
also identify two personally important ‘target situations’ that cause significant anxiety and impact upon their daily
life. Based upon the formulation and identified target situations, participants randomised to the PAT-A©
intervention will receive up to 12 individualised, one-to-one therapy sessions. Initial emotional literacy training
sessions will be followed by a bespoke, modular, needs-based treatment approach utilising one or more of the
following approaches: Mindfulness, Coping with Uncertainty in Everyday Situations (CUES), social anxiety and
graded exposure within Virtual Reality Environments. Participants in the control arm will receive two psycho-
educational sessions focussing on understanding and describing emotions and be signposted to healthcare
provision as required. Data will be collected through quantitative and qualitative methods.
Discussion: This feasibility pilot trial serves as the first stage in the development and evaluation of a manualised
personalised, evidence-based psychological therapy treatment for anxiety in autistic adults. Study outcomes will be
used to inform an application for a fully powered multi-site intervention trial of adults and young people.
Trial registration: ISRCTN, ID: 15881562. Retrospectively registered on 9 August 2019.
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Background
Autistic people experience difficulties with social com-
munication, social interaction and restricted, repetitive
patterns of behaviours [1]. Mental health conditions are
significantly more prevalent in autistic adults compared
to the general population [2, 3]. In particular, estimates
of clinically significant anxiety over the lifespan indicate
a prevalence of between 30 and 60% in samples of autis-
tic adults [4–6]. Anxiety presentations in autistic people,
however, can vary and may have a distinct presentation,
which may be underpinned by the individual’s autism-
related profile. The symptoms may include social dis-
comfort not associated with a fear of negative evaluation;
engagement in compulsive behaviours that are not
motivated by distress relief or idiosyncratic fears and
phobias; and significant difficulties coping with change or
uncertainty [7].
Recent research studies using the World Health Or-
ganisation International Classification of Functioning (IC
F; [8] highlight that the impact of autism and co-existing
mental health conditions extends far beyond core symp-
tom domains to include personal interests/activities,
engagement with peers, family members and the local
community, as well as other areas of physical and mental
wellbeing [9, 10]. The range and frequency of life dis-
advantages for autistic adults (across the socio-economic
spectrum, including education, employment, finances,
social services, criminal justice system contact, and victim-
isation across the life-course) has been reported in a re-
cent study [11]. Autistic adults have reported significantly
more disadvantages than non-autistic adults and these dis-
advantages significantly mediated the association between
an autism diagnosis and depression, anxiety, and life
satisfaction. Furthermore, data from the Adult Autism
Spectrum Condition Cohort–UK (ASC-UK; Brice et al.,
what do autistic people tell us about their anxiety and
treatments and services recieved? Findings from a large
UK survey, in preparation) suggests that anxiety signifi-
cantly limits education and employment opportunities
and reduces quality of life.
In spite of increased interest in understanding the men-
tal health needs of autistic adults [12], data from various
sources indicates that health services are not currently
meeting autistic adults’ needs [13, 14]. In the UK, National
Health Service (NHS) mental health teams currently
provide treatment for a range of anxiety disorders with
cognitive behavioural therapy (CBT) offered as the
predominant intervention [15, 16]. Evidence-based CBT
approaches include a core set of features such as Socratic
questioning, guided discovery and collaborative empiri-
cism. These features rely on interaction with a therapist,
flexibility in thinking and emotional literacy, all of which
autistic people may struggle with [17]. Furthermore, some
CBT techniques may be difficult for people with autism,
such as the ability to change behavioural routines and
identify how to modify cognitive processes [18]. Difficul-
ties with imagination [19] mean that standard techniques,
such as imaginal exposure, may not always be accessible,
without modification. All of these features can impact
upon engagement and establishing a therapeutic relation-
ship, hence the need for bespoke personalised approaches
to the delivery of psychological therapies specifically
developed to address the anxiety experienced by autistic
people that are in addition to reasonable adjustments to
support access to these therapies [20, 21].
Recognition of anxiety in autistic individuals may be
limited as a consequence of factors such as alexithymia
(difficulties recognising, understanding and describing
emotions) and/or limited social communication skills
[22]. In addition, autistic individuals often experience
symptoms of a range of anxiety disorders concurrently
[23]. This means that existing CBT packages designed
for specific anxiety diagnoses in the general population
may not be appropriate if specific aspects of the individ-
ual’s anxiety profile are not addressed and/or the treat-
ment plan does not take sufficient account of the
interaction between anxiety and autism. Many current
psychological treatments are not always/routinely pro-
vided within a setting sufficiently adapted for people
with autism or with reasonable adjustments that would
facilitate access (Brice et al., in preparation). These fac-
tors partly explain why currently available CBT interven-
tions may not be accessible and appropriate for many
autistic adults presenting to primary care and mental
health services [16]. The implications are that anxiety
treatments should be designed and personalised for
autistic adults in order to facilitate access to treatment
and maximise the chances of effectiveness.
Understanding and designing appropriate autism-
informed psychological therapies for mental health con-
ditions, and, in particular anxiety, are recognised key pri-
orities for autistic individuals [24] and for the autism
research community (first and fourth in the 2016 Top
Ten research questions from the Autistica-led James
Lind Alliance Priority Setting Partnership; [25]). In
addition, both the national adult autism strategy [26]
and National Institute for Health and Care Excellence
(NICE) clinical guidelines [27] highlight the prioritisa-
tion of developing high-quality, effective psychological
interventions for autistic adults.
The majority of published research on the develop-
ment of psychotherapies for anxiety in autism has fo-
cussed upon children and adolescents [28]. Some studies
with adults have focussed on a range of intervention ap-
proaches, methods and measures of therapeutic change
in a small number of single case reports [29–31]. One
single-blind randomised trial of group CBT for autistic
adults, found no difference in anxiety at follow-up
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between those allocated to treatment or a waiting-list
control [32]. Novel interventions combining Virtual
Reality Environments (VREs) and CBT for the treatment
of specific phobias have demonstrated feasibility and ac-
ceptability and some evidence of acceptability and effi-
cacy in autistic adults [33]. Trials of mindfulness-based
psychotherapies have also obtained favourable outcomes
[34, 35], for a range of symptoms such as anxiety, de-
pression and rumination. Other trials of CBT for autistic
adults similarly aim to improve emotional regulation
and functioning as opposed to working specifically with
anxiety-based presentations. Given the growing evidence
that difficulty in tolerating uncertainty is associated with
the development and maintenance of clinically signifi-
cant anxiety in autistic adults [36–39], interventions
aimed at increasing the ability to cope with uncertainty
have been piloted for feasibility and have demonstrated
promise as a treatment option [40].
The Personalised Anxiety Treatment–Autism (PAT-
A©) randomised feasibility trial is designed to investigate
the feasibility and acceptability of delivering a manualised
individualised anxiety treatment package for autistic adults
with a variety of anxiety presentations. This formulation-
driven and personalised psychological approach to therapy
aims to provide treatment for the diverse and often co-
existing nature of anxieties found in autistic adults whilst
accommodating the specific needs and personal preferences
(e.g. sensory reactivity, social motivation, approaches
to learning) of the individual.
Methods/design
Study design
This study is a pilot feasibility randomised controlled,
single-centre trial (pilot RCT) with a blind-to-group out-
come assessor. The trial has two arms; an intervention
arm (Personalised Anxiety Treatment–Autism; PAT-A©)
and a control arm (Current Clinical Services Plus; CCSP).
Adults aged 18 years or above with a clinical diagnosis of
an autism spectrum disorder and at least one clinically
recognised anxiety disorder that may benefit from psycho-
logical therapy will be included. All recruited participants
will live in North East England and have accessed care
from a local NHS mental health trust.
Aims and objectives
This is a feasibility trial, hence recruitment, acceptability,
retention, completion of outcome measures and adher-
ence of participants to the two study arms (PAT-A© and
CCSP) will be assessed as the main outcomes. Other
outcomes, such as the potential reduction in anxiety and
increased engagement in ‘target situations’ (determined
collaboratively by the participant and therapist) will also
be measured to inform future trial design.
Study registration and ethical approval
A favourable ethical opinion was provided by NHS
Health Research Authority and a Research Ethics Com-
mittee (Wales REC 5, IRAS ID: 235805). Brief eligibility
procedure and written informed consent will be obtained
from all individuals by the research associate (RA) prior to
baseline assessment.
Sample size
This pilot feasibility trial is not powered to estimate a
target difference in relative effectiveness, but rather to
address feasibility and acceptability of delivering an indi-
vidualised anxiety treatment package for autistic adults
with a variety of anxiety presentations to inform a future
definitive trial. We aim to recruit up to 40 participants.
This number is based on recommendations for good
practice in feasibility studies [41].
Recruitment and eligibility criteria
Participants will be recruited from clinical teams within
Cumbria, Northumberland, Tyne and Wear NHS Foun-
dation Trust (CNTW). Clinical teams that treat people
who meet the eligibility criteria described below will be
approached by the RA who will outline the trial to them
and explain the recruitment procedures (adult mental
health and autism diagnostic services). Clinicians will be
encouraged to screen their caseload and waiting list for
autistic people who meet eligibility criteria before briefly
discussing the trial with them and returning an Expres-
sion of Interest Form to the RA. The RA will then con-
tact the prospective participant with full information
about the trial. If, after reading this information, they are
still interested, the RA will arrange a meeting to discuss
the trial in more detail, answer any questions that the
participant might have and, if appropriate, take written
informed consent (although participants can take up to
a week to decide whether they would like to take part
following this meeting). The Consent Form asks partici-
pants to confirm in writing that they understand what
their participation in the study will involve, understand
their rights as a participant (e.g. right to anonymity, right
to withdraw, how their data will be handled) and that
healthcare professionals involved in their care may be in-
formed of their participation. As a viable fall-back strat-
egy, participants can also be recruited via the Adult
Autism Spectrum Cohort–UK (ASC-UK); a large, longi-
tudinal research cohort of autistic adults, many of whom
have previously expressed an interest in taking part in
research. Monitoring of trial progress (including recruit-
ment) will be discussed at fortnightly meetings including
co-investigators, RA and, where appropriate, trial
therapists.
Inclusion criteria for participation in the trial include:
an autism spectrum diagnosis given by an NHS clinical
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team; aged 18 years or older; resident in the Northum-
berland, Tyne and Wear area; an ability to provide in-
formed consent and the verbal comprehension skills
required to participate in interviews, talking therapy and
the completion of questionnaires. Participants will also
be identified as experiencing clinically significant anxiety
by an NHS clinician. Intellectual ability will not be for-
mally assessed so the trial is in line with NHS clinical
practice where clinicians take pragmatic decisions about
treatment and people’s abilities to engage in treatment,
rather than basing treatment access on cognitive assess-
ment scores. Participants with co-existing physical and/
or mental health conditions will not be excluded unless
these conditions significantly affect capacity to engage in
the psychological therapy delivered as part of this study.
Participants will not be excluded on the basis of having
received previous or ongoing pharmacological treatments
for anxiety.
Exclusion criteria for participation in the trial include:
people without an autism diagnosis; people under the
age of 18 years; those already engaged in an ongoing
psychotherapeutic treatment for anxiety (in the 3
months prior to consent); people who are experiencing a
physical or mental health condition that would signifi-
cantly impact on their ability to engage in psychological
therapy for anxiety; people unable to provide informed
consent (Fig. 1).
Randomisation
All consented eligible participants who have completed
baseline assessment will be randomised following the
formulation and treatment planning meeting with the
study team, to either the intervention (PAT-A©) arm or
the control (CCSP) group via computer-generated se-
quence blocks (Sealed Envelope; www.sealedenvelope.
com/). A simple randomisation schedule will be used
without blocking or stratification as this will allow us to
address the aims of the trial. A research administrator
independent of the trial will oversee this process, ensur-
ing that the RA remains blinded to the outcome of ran-
domisation. One of the trial therapists (PW) will inform
the participant of the outcome of randomisation and this
will also be recorded in the participant’s NHS electronic
patient record. Due to the design and configuration of
this trial, it is not possible for participants to remain
blinded to group; however, data analysis will be con-
ducted by the RA who is blind to group.
Study interventions
PAT-A© intervention
Taking account of the formulation and treatment plan,
participants will be offered a bespoke intervention pack-
age utilising one or more manualised PAT-A© modules.
All participants will receive a manualised Understanding
and Describing Emotions (UaDE) module, which aims to
develop a person’s ability to understand emotional states,
how different situations and thoughts impact upon these
states, and assessing current emotional-regulation strat-
egies. Ensuring that individuals have the requisite know-
ledge and language in order to engage in conversations
about physiological arousal and emotions during therapy
has been highlighted as a key adaption when using CBT
with autistic adults [17]. The module length depends on
the participant’s pre-existing knowledge and ability in
relation to emotions. The module is a scaffolding
approach to enable the participant to understand other
PAT-A© treatment modules.
Following on from the UaDE module, the participant
will receive an intervention including one or more of the
following manualised treatment modules (Fig. 3). All
modules have been designed to stand alone but can also
be used in combination where appropriate.
Mindfulness Mindfulness-based therapies have demon-
strated effectiveness for a range of mental health condi-
tions [42] and have been adapted for use with autistic
adults [34, 35, 43]. This module aims to provide individ-
uals with skills to enable them to tolerate emotional dis-
tress in everyday situations and/or facilitate engagement
with anxiety-provoking situations and behavioural exper-
iments outlined in other treatment manuals of the PAT-
A© intervention programme. The Mindfulness module
has been designed to include a Mini Mindfulness ap-
proach (two to three sessions in duration) and a Full Ap-
proach (six to eight sessions) depending upon the needs
of the participant.
Coping with Uncertainty in Everyday Situations
(CUES-A©) Intolerance of Uncertainty (IU) has been
proposed as an important trans-diagnostic mechanism
in the development of anxiety in autistic adults [22]. The
focus of the CUES-A© intervention programme [40, 44]
is to support participants to develop their awareness,
gain confidence in their ability to recognise and manage
their own IU through collaborative CBT strategies.
Social anxiety Although autistic adults may experience
fear and anxiety in social situations for a variety of rea-
sons, this module is designed for those where social-
evaluative concerns are the predominant difficulty. It
contains the main elements commonly used in recom-
mended treatments for social anxiety [45] that have been
adapted for autistic adults; for example, ensuring that
any social communication difficulties have been assessed
and taken into account.
Virtual Reality Environment-delivered treatment for
phobias The Virtual Reality Environment (VRE)
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intervention programme uses visual images projected
onto the walls and ceilings of a screened room over four
20-min sessions. Participants interact with and navigate
through a specific phobia scenario with the support of a
therapist. Feasibility studies support the use of this VRE
as an acceptable and effective treatment for specific pho-
bia in both autistic young people and adults [33, 46, 47].
CCSP (control arm)
Participants will be offered two psycho-educational
sessions focussing on understanding and describing
emotions. They will then be signposted to services that
are available to them as part of usual care.
Baseline characterisation
Following informed consent taken by the RA, initial as-
sessment measures will be completed with the participant.
The main initial assessment will be the Anxiety and Re-
lated Disorders Interview Schedule for DSM-5: Adult Ver-
sion (ADIS-5; [48]) undertaken with the participant and
administered by the RA (a trained clinical psychologist).
This structured interview is designed to identify current
anxiety, mood, obsessive-compulsive, trauma and related
disorders (e.g. somatic symptoms, substance use) accord-
ing to the Diagnostic and Statistical Manual for Mental
Disorders, 5th edition (DSM-5) criteria [1]. In addition, the
trial team has developed an additional Summary Form to
Fig. 1 Personalised Anxiety Treatment–Autism (PAT-A©) Consolidated Standards of Reporting Trials (CONSORT) Flow Diagram
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capture specific phenomena that research indicates may
be particularly related to anxiety experienced by autistic
people (e.g. the presence of sensory sensitivities, IU). The
ADIS-5 also records historical information regarding pre-
vious or concurrent anxiety-related treatments and signifi-
cant life events.
Following the anxiety assessment, the RA and partici-
pant will jointly identify and agree two personally im-
portant target situations that cause significant anxiety
and impact upon the participant’s everyday functioning
and quality of life. For both self-identified targets the
participant will be asked about the situation that is asso-
ciated with anxiety including frequency, their reactions
to that situation (symptoms and intensity), whether they
worry about the situation in advance, and how it inter-
feres with daily functions and activities. These details
will be summarised by the RA in a written vignette. The
protocol was developed by the Research Units on Paedi-
atric Psychopharmacology (RUPP) Autism Network [49]
and has demonstrated high levels of agreement between
expert raters. Arnold et al. [49] reported an Intraclass
Correlation Coefficient (ICC) of 0.895 across a panel of
five raters. This has been a preferred outcome measure
in our previous trials, and it has demonstrated utility in
recording change in anxiety associated with a specific
real-life goal or situation [46, 47, 50–52].
The RA will also complete the: Session Engagement
Form (developed by the research team) This form re-
quires the RA to consider the participant’s engagement
in the assessment process using five key markers, each
rated on a 4-point scale: (1) level of verbal communica-
tion, (2) focus/attentiveness, (3) understanding of key
concepts, (4) ability to flexibly move between topics and
(5) speed of processing information.
A set of self-report measures will also be completed
during the baseline assessment to enable characterisa-
tion of the individual’s autism profile and their anxiety.
These include:
 Social Responsiveness Scale (SRS-2; [53]: the SRS-2
is a standardised self-report questionnaire used
extensively to rate the social communication
difficulties of autistic adults and children. Estimates
of internal consistency of between .94 to .96 have
been reported whilst the predictive validity of the
adult form found a specificity level of .60 and
sensitivity of .86 [54]
 Anxiety Scale for Autism–Adult (ASA-A©; [55]):
the ASA-A© is a 20-item self-report measure
designed to measure anxiety in autistic adults. It
consists of four subscales: Social Phobia (SP),
Anxious Arousal (AA) and Uncertainty (U). The
ASA-A© can be summated to provide a total anxiety
score, as well as broken down into subscale scores
(the sum of items within a subscale). All items are
rated on a 4-point Likert scale, from 0 (‘never’) to 3
(‘always’). The ASA-A© was adapted from the
Anxiety Scale for Children Autism Spectrum Dis-
order (ASC-ASD©; [56]) in collaboration with pro-
fessionals and autistic adults, to make it suitable for
use in an adult population. The authors indicate that
a total score of ≥ 28 on the ASA-A© may indicate
the presence of significant levels of anxiety. At
present, indicative cut-offs are not available for the
subscales. Preliminary analysis of the psychometric
properties of the ASA-A© indicate excellent internal
consistency (Cronbach’s α total score = .899, Uncer-
tainty subscale = .834, Anxious Arousal Subscale =
.845, Social Phobia Subscale = .847), excellent 1-
month test-retest reliability (.823) and robust con-
vergent and divergent validity [55]
 Hospital Anxiety and Depression Scale (HADS;
(Zigmond AS, Snaith RP. The Hospital Anxiety and
Depression Scale, submitted)): the HADS is a 14-
item self-report questionnaire widely used within a
variety of community and psychiatric populations in
order to measure symptoms of anxiety (seven items)
and depression (seven items). Research demonstrates
promising internal consistency (HADS-A, α =
82–.84; HADS-D, .60–.72) and convergent validity
(WEMWBS, r = −.45 to −.60, p < .001; SDQ
emotional scale, r = .80, p < .001; DSM-5 DAS
anxiety scale, r = .71, p < .001 and the PHQ-9
depression scale, r = .56, p < .001) when used with
autistic individuals [57]
 WHO Quality of Life-BREF (WHOQOL-BREF) and
Disabilities module plus Autism Addendum: the
WHOQOL-BREF [58] is an abbreviated 26-item
questionnaire covering four domains of quality of life
(Physical health, Psychological health, Social
relationships, and Environment). It is currently the
most commonly used quality of life measure within
autistic adult populations [59]. In order to ensure
relevance to our participant group the WHOQOL-
BREF will be used alongside the WHO Disabilities
module [60] and the Autism Addendum recently
developed by our group [61]. Internal consistency
for this measure is excellent (α = 0.93) whilst the
structural validity of the WHO factor structure is
acceptable for use with autistic people (CFI = 0.902,
GFI = 0.886, RMSEA = 0.059, PCLOSE = 0.006,
χ2 = 519.90, df = 242, p < 0.001) [61]
 EuroQoL 5 dimensions, 5 levels health survey (EQ-
5D): the EQ-5D [62] is a generic measure of health-
related quality of life allowing for the calculation of
Quality Adjusted Life Years (QALYs), commonly
used by the NHS to measure treatment effectiveness.
There is evidence that the measure demonstrates
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convergent validity with all items of the World
Health Organisation-Five Well-Being Index
(WHO-5; [63])
 Toronto Alexithymia Scale-20 (TAS-20; [64]: the
TAS-20 is one of the most commonly used measures
of alexithymia comprising of three subscales
covering difficulty describing feelings, difficulty
identifying feelings, and externally-orientated
thinking. It has demonstrated test-retest reliability
(r = 0.79–0.92), convergent validity with other
measures of alexithymia such as the Bermond and
Vorst Alexithymia Questionnaire-form B (BVAQ-B;
r = 0.48–0.77, p < 0.05) and discriminant validity,
over time, in a sample of autistic adults and controls
(time 1, Exp(B) = 1.22, CI (1.09–1.36), p < 0.001; time
2, Exp(B) = 1.17, CI (1.06–1.29), p < 0.01) [65]
 Waisman Activities of Daily Living Scale (W-ADL;
[44]: the Waisman Activities of Daily Living Scale
(W-ADL) is a measure of independence validated in
people with a broad range of developmental
disability diagnoses. Analysis indicates that it is
reliable over time (κ = 0.92–0.93), with high levels of
internal consistency across disability groups
(Cronbach’s α = 0.88–0.94) and criterion validity
when compared to the Vineland Screener Adaptive
Behavior Composite Score (r = 0.78)
 Reasonable adjustments: an adaptation of an existing
checklist, will be utilised. As autistic adults state that
they would like professionals to take into account
their sensory sensitivities or neurological differences
[12, 13], we will aim to accommodate these within
the intervention by asking participants as part of the
baseline characterisation about their preferred
means of communication, factors which may make
attending sessions easier/more difficult, current
emotional-regulation techniques, special interests
and considerations regarding the involvement of
family members, friends or independent advocates
Formulation of anxiety and treatment planning
Once the assessment is complete, the RA will compile a
standardised assessment report including the following
information:
 Current (and, where relevant, historical) mental
health and physical health diagnosis(es) including
severity scores from the ADIS-5 diagnostic interview
 Relevant personal details/background, the impact
autism and anxiety may have on the current
functioning and a summary paragraph of each
anxiety/mental health disorder
 SRS-2 and TAS-20 summary scores
 A summary of reasonable adjustments required for
therapy
 Two target-situation vignettes
 The Session Engagement Form
The assessment report for each consented participant
will be discussed at a meeting of trial therapists and se-
nior members of the research and clinical team con-
vened by the RA. During this meeting, a formulation of
the participant’s current anxiety-related difficulties will
be developed and an individualised treatment plan
agreed prior to randomisation. Decisions regarding treat-
ment planning will be informed by a treatment algo-
rithm developed by the clinical team as part of the trial.
The treatment algorithm uses the assessment informa-
tion and the participant’s target situations to plan treat-
ment using a combination of the treatment modules
available. Following the answering of any questions on
the presentation, the RA will leave the room, and the
clinical team will agree a treatment plan. In addition, as
part of the evaluation of the feasibility of the formulation
and treatment planning procedures, prior to the meet-
ing, the RA will use the treatment algorithm to identify
the treatment plan that they suggest, and seal this in an
envelope to be opened at the end of the formulation
meeting. Levels of agreement in treatment plans between
the RA and the clinical team will be calculated; however,
for the purpose of this pilot RCT the clinical team’s de-
cision will be final.
Feasibility and acceptability outcomes
The primary outcomes for this feasibility and acceptabil-
ity pilot RCT will be recruitment (number of expressions
of interest, how many of those expressing interest go on
to consent (and, if not, why not?), how many are ex-
cluded and the reasons for this), acceptability (including
acceptability of the randomisation procedure), retention,
completion of outcome measures and treatment adher-
ence. Treatment adherence will be measured by record-
ing the percentage of sessions that each participant
attended, compared with those scheduled and reporting
the median, minimum and maximum for the sample. As
treatment is individualised and, therefore, variable in
length, there is no fixed number of sessions for a
‘complete’ dose. The therapist will also record each
participant’s engagement in homework tasks (a core
component of CBT) at each session. The participant’s
engagement will be rated on a 5-point scale ranging
from ‘not attempted’ to ‘extra homework completed’.
Each participant’s engagement in homework will be
combined into an average score over the course of their
treatment and the median, minimum and maximum at
sample level will be reported.
An opportunity to participate in a semi-structured
qualitative interview will be offered to all participants 3
months post intervention, with the aim of gaining
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information about the acceptability of the trial and treat-
ment processes from the participant’s perspective.
Topics to be covered will include the acceptability of
randomisation, feedback on both the PAT-A© interven-
tion and CCSP and the appropriateness of baseline and
outcome measures used. Participants will also be asked
if they have experienced any changes (either positive or
negative) in any other anxiety-related situation not
otherwise covered in the target situation(s).
Other outcomes
As the PAT-A© intervention has been developed to im-
prove engagement with the specific target situations, the
target situation rating will also be considered as an out-
come measure to identify symptom change over time.
As previously described two target situation vignettes
will be developed in collaboration with the participant
using baseline assessment data. Both vignettes and the
severity of difficulties within the target situation are then
reassessed 3 months post intervention by the RA. Degree
of improvement will be rated by an expert panel of re-
searchers and clinicians, blinded to the treatment group,
which will compare the anonymised vignettes from base-
line and follow-up and identify whether there has been
any change since baseline. A 9-point scale (from 1 ‘nor-
malised’, 2 ‘markedly improved’, 3 ‘definitely improved’,
4 ‘equivocally improved’, 5 ‘no change’, 6 ‘equivocally
worse’, 7 ‘definitely worse’, 8 ‘markedly worse’ to 9 ‘dis-
astrously worse’) will be used to rate change between
baseline and 3 months post intervention. Comparisons
of change scores for the two vignettes between the two
groups across time (baseline to 3- month follow-up) will
then be made. The research team also plans to repeat
the target-situation interview and ratings at 12 months
post intervention.
In addition to the target situations, the following ques-
tionnaire data will be collected at 3 months post interven-
tion to allow analysis of differences between baseline and
follow-up across the intervention and control groups:
• Anxiety: assessed using the full-scale score on the
ASA-A
• Quality of life: assessed using full-scale score and
subscale scores on the WHOQoL-BREF plus the
ASQoL and disabilities module
• Health-related quality of life: assessed using full-scale
score on the EQ-5D
The Clinical Global Impression of Improvement (CGI-
I) will be used to assess global clinical change between
baseline and 3 months post intervention. The CGI-I is a
standardised framework for clinicians to assess to what
extent participants’ symptoms have improved or wors-
ened using a 7-point scale (1 – very much improved; 2 –
much improved; 3 – minimally improved; 4 – no
change; 5 – minimally worse; 6 – much worse; or 7 –
very much worse). The RA, who is blind to group and
clinically trained, will rate global improvement using all
available data from baseline and 3-month post-
intervention follow-up, including:
 ASA-A
 WHOQoL-BREF plus ASQoL and disabilities module
 EQ-5D
 HADS-D (depression subscale)
 Target-situation vignettes
 Responses to the interview question about change in
an anxiety-related situation not otherwise included
in the target-situation vignette(s)
Ratings of 1 (very much improved) and 2 (much im-
proved) are regarded as significant ‘improvement’, rat-
ings of 7 (very much worse) and 6 (much worse) are
regarded as significant ‘worsening’ and ratings of 3–5
(inclusive) are regarded as ‘no change’. A percentage of
the participants’ CGI-I score will be independently rated
by a second rater to assess inter-rater reliability.
Full details of the measures repeated at follow-up can
be seen in Fig. 2.
Data collection and management
Baseline assessment and follow-up measures will be col-
lected by a RA blinded to the outcome of randomisation.
All participants will be allocated a unique number that
will be used to identify them on all paper assessment
forms throughout the trial. All data collected on paper will
be inputted into a statistical analysis software system and
all identifying data will be stored separately. A proportion
of the data recorded on paper will be inputted electronic-
ally by two researchers independently to measure data-
entry error rate. Missing questionnaire data at item level
will be managed according to the manual for each ques-
tionnaire. If no manual exists, any published precedents
will be consulted (e.g. [66]), or the mean imputed score
for that subscale/full-scale (as appropriate) will be used,
providing that no more than 30% of the data is missing.
All study data will be treated in accordance with the latest
Directive on Good Clinical Practice (2005/28/EC).
A Data Monitoring Committee (DMC) will not be re-
quired as this is a pilot feasibility trial. The RA will discuss
challenges with data collection with the lead investigators.
The RA will be responsible for ongoing review of data
completeness and any concerns will be discussed within
the wider research team and the sponsor as appropriate.
Treatment fidelity and engagement
The PAT-A© intervention has been designed to be de-
livered by clinical psychologists or suitably qualified
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CBT therapists with experience of working with autistic
adults. Therapists will receive supervision every 2 weeks,
alongside monthly group supervision and access (as and
when required) to a consultation group of researchers
and clinicians (comprising experts in CBT and adapting
interventions for autistic people). A Session Recording
Form will be completed by the therapist after each
therapy session in order to track the treatment modules
and specific components received by the participant and
to assess therapist adherence to core CBT techniques (e.g.
guided discovery, ‘homework’ setting). Where possible,
therapy sessions will be audio-recorded in order to under-
take independent fidelity ratings after all participants have
been treated. Members of the research team will review
audio-recorded sessions to ensure fidelity to the treatment
module(s) as they are defined in the manual(s).
The session engagement checklist used during assess-
ment (described above) will also be used after each
Fig. 2 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) Figure: schedule of enrolment, intervention and assessment
within the Personalised Anxiety Treatment–Autism (PAT-A©) trial
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therapy session to assess and record the participant’s
engagement with treatment and to facilitate therapeutic
review including impact of any required autism informed
adjustments to therapy, or additional adjustments
required.
Modification or discontinuation of study interventions
A primary intervention approach is endorsed during the
PAT-A anxiety formulation; however, this may be modi-
fied in light of new information and progress during
therapy. To ensure that the intervention can be imple-
mented, specific components of another module will be
considered within the context of a developing formula-
tion during therapy supervision between the therapist
and clinical supervisor. When an entirely different
intervention module is indicated (a deviation from the
original PAT-A formulation), a consultation group, con-
sisting of members of the trial team, will be convened.
The recommendations of the consultation group will be
recorded, although treatment decisions remain with the
therapist and clinical supervisor.
Participants will be entitled to discontinue their treat-
ment at any time and without having to give reason. In-
terventions may also be discontinued when both the
therapist (in consultation with the clinical supervisor)
and participant agree that continuing with therapy is un-
likely to be beneficial due to factors such as concurrent
life events, participant motivation, session attendance
and engagement. Treatment will be discontinued if a
screening error becomes apparent during treatment, e.g.
the identification of a clinical presentation that meets
the exclusion criteria or if a significant or immediate
clinical risk is identified, and continuation of PAT-A
would be contraindicated. Such decisions will be made
through clinical supervision and in consultation with the
participant. In any such eventuality, the trial therapist
will ensure that the participant is referred to an appro-
priate service for ongoing clinical support.
Adverse event recording
Any adverse event (defined within the trial as unex-
pected events) will be recorded using a pre-existing
checklist [67]. Events to be recorded include deterior-
ation of existing symptoms, the emergence of new symp-
toms, significant changes in life circumstances and
strains in family relationships. All adverse events will be
discussed in supervision and the Trial Management
Group for those defined as significant will be dealt in ac-
cordance with relevant NHS protocols and reported to
the sponsoring NHS Trust and the reviewing Regional
Ethics Committee as per the standard operating proced-
ure of the sponsoring NHS Trust. All adverse events will
be recorded and filed in the Trial Management File
(TMF). Any significant adverse events that occur as a
result of the trial intervention(s) will be reported in any
publications and the same may be true for an adverse
event that was not caused by study interventions but
likely had a significant impact on a participant’s capacity
to engage successfully with trial interventions.
The trial has been indemnified by Newcastle Univer-
sity and Cumbria, Northumberland, Tyne and Wear
NHS Foundation Trust. It is not expected that partici-
pants will experience any significant harm as a result of
taking part in this trial. Should any participant experi-
ence significant harm then this would be reported to the
sponsoring trust, which would manage this through their
standard procedures.
Statistical analysis
As this is a feasibility and acceptability pilot study, ana-
lyses will be mainly descriptive. Formal power calcula-
tions are not appropriate as the study is not designed to
test for a difference between treatments. Feasibility will,
therefore, be explored by examining:
 The number of expression-of-interest forms
received, the number who go on to consent and
those who either choose not to take part (including
reasons given) and those who are ruled out on
eligibility grounds
 Take-up, attendance and engagement with the PAT-
A© intervention and CCSP
 Completion of follow-up data at 3 months and 12
months post intervention
 Qualitative data regarding the acceptability of PAT-
A© from the participants’ perspective
We will also undertake some preliminary analysis of
treatment effects, and follow a pre-existing statistical
analysis plan. The difference in mean change as assessed
by the main outcome measure from our previous trials
(‘target-situation’ vignettes) and anxiety screening tools
will be examined between the groups from baseline to 3
months post intervention with accompanying 95% confi-
dence intervals. Results will be interpreted cautiously be-
cause of the size of the study, the possible imbalance in
pre-randomisation baseline covariates and the range of
interventions offered to participants within the CCSP
arm of the trial (Fig. 3).
Dissemination plan
Dissemination of the trial findings will be undertaken in
several ways. We will work closely with autistic people,
who will review the findings alongside members of the
research team and assist with ensuring that the results
are interpreted and reported in a meaningful way. A
short webinar about the findings will be created and
hosted on our website(s) with links to this shared within
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dissemination events and with key local and national
stakeholders. A series of reports will be written in
accessible language and will include ‘EasyRead’ versions
to maximise accessibility. We will prepare newsletters/
reports for autistic people and their families, profes-
sionals, commissioners and other key agencies. Results
will be presented at academic meetings and research
papers submitted to open-access, peer-reviewed scientific
journals.
Discussion
Significance
The PAT-A© intervention is a novel approach to
treating anxiety conditions in autistic adults. It is a
highly individualised, modular and formulation-driven
psychological therapy that aims to improve both the
understanding and management of emotions and by
targeting one or more situations salient to the partici-
pant, to improve functioning and reduce anxiety. If
this approach to anxiety treatment in autistic adults is
found to be acceptable (to autistic people and profes-
sionals) and effective it could be used widely in
healthcare settings and thus improve everyday func-
tioning and quality of life for affected adults and
reduce the burden of care for individuals, families and the
wider community. Study outcomes will be used to inform
an application for a fully powered multi-site intervention
trial of adults and young people.
Strengths and limitations
The CCSP (control) arm of this trial consists of usual
care from local services with two additional sessions fo-
cussing upon emotional recognition skills. The decision
to offer an enhanced level of care reflects feedback from
the autistic community about the acceptability of trial
methods. This enhanced package may support retention
of participants who are randomised to the control arm
and will provide a stringent test in a fully powered trial.
Our primary method of recruitment potentially ex-
cludes adults who struggle to, or do not, engage with
primary care or mental health services [58]; however,
consideration of methods to include participants from
other settings is beyond the scope of this feasibility trial,
which is focussed on recruitment from mental health
services. Should the PAT-A© intervention demonstrate
efficacy in a fully powered trial, then a next step would
be to consider the development of a modified treatment
package for autistic people who may require additional
support to access services.
Fig. 3 Personalised Anxiety Treatment–Autism (PAT-A©) treatment modules. Note: the number of sessions devoted to any PAT-A package
depends upon the participant’s formulation, treatment plan, and the ability to engage in the therapeutic process
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Trial status
Protocol Version 2.0 (1 March 2019). The first partici-
pant was recruited in November 2018. At the time of
submission, the PAT-A© trial is currently recruiting. Re-
cruitment is expected to continue until November 2019.
The PAT-A© trial is monitored by the sponsoring NHS
trust. The trial is registered with ISRCTN and the NIHR
Portfolio.
Trial sponsorship
The PAT-A trial is sponsored by Cumbria, Northumber-
land, Tyne and Wear NHS Foundation Trust. Address:
St Nicholas Hospital, Jubilee Road, Gosforth, Newcastle
upon Tyne, Tyne and Wear, NE3 3XT. Tel: 0191
2081356. Web: www.cntw.nhs.uk
Abbreviations
ADIS-5: Anxiety and Related Disorders Interview Schedule for DSM-5: Adult
Version; ASA-A: Anxiety Scale for Autism - Adults; ASC: Autism Spectrum
Condition (please note: we use the this term throughout the paper to refer
to any Autism Spectrum Condition including Asperger’s syndrome);
CBT: Cognitive behavioural therapy; CUES: Coping with Uncertainty in
Everyday Situations; HADS: Hospital Anxiety and Depression Scale;;
NHS: National Health Service; NICE: National Institute for Health and Care
Excellence; PAT-A©: Personalised Anxiety Treatment in Autism–Adult; SRS-
2: Social Responsiveness Scale; TAS-20: Toronto Alexithymia Scale-20;
UK: United Kingdom; VREs: Virtual Reality Environments (VREs); W-
ADL: Waisman Activities of Daily Living Scale; WHOQOL-BREF: World Health
Organisation Quality of Life-BREF
Acknowledgements
The authors gratefully acknowledge the valued contribution of the following:
• Our advisory group
• Professor Helen McConachie for her valuable contributions regarding the
PAT-A concept, and trial methods
• Mr Colin Wilson for his role within the PAT-A team and for providing
consultation on trial methods and materials
• The UK autism research charity Autistica for funding this study as part of
the Autism Adulthood and Ageing Research Programme at Newcastle
University
Authors’contributions
JR and JP are co-lead investigators for the trial. JP applied for, and was
awarded, funding. JP leads governance and reporting. JP co-designed the
PAT-A© trial, the PAT-A© treatment and contributed to the treatment
manuals. JP co-supervises the research team with JR. JR co-designed the
PAT-A© trial, the Autism-specific Anxiety Summary Form that was used in
addition to the diagnostic interview, the PAT-A© treatment and contributed
to the treatment manual and is part of the PAT-A© formulation team. JR co-
supervises the research team and will supervise the statistical analysis. MF is
a co-investigator. He co-designed the PAT-A© trial, the Autism-specific
Anxiety Summary Form that was used in addition to the diagnostic
interview, the PAT-A© treatment and contributed to the treatment manuals.
With BI, he leads the formulation team. BI is a co-investigator. He co-
designed the PAT-A© trial, the PAT-A© treatment and contributed to the
treatment manuals. He supervised the therapists and leads recruitment
through Cumbria, Northumberland Tyne and Wear NHS Foundation Trust,
supported by research nurses. ALC is a co-investigator. She co-designed the
PAT-A© trial, the PAT-A© treatment and contributed to the treatment
manual and is a member of the PAT-A© formulation team. SB is a clinical
research associate. He is responsible for the day-to-day assessment and
recruitment of participants. He co-designed the Autism-specific Anxiety
Summary Form that was used in addition to the diagnostic interview, the
PAT-A© treatment and contributed to the treatment manual and is part of
the PAT-A© formulation team. PW is a trial therapist. He is responsible for
the delivery of the day-to-day delivery of the PAT-A© intervention. He co-
designed the PAT-A© treatment manuals and is part of the PAT-A©
formulation team. GE is a trial therapist. She delivers the PAT-A© intervention,
co-designed the PAT-A© treatment manuals and is part of the PAT-A©
formulation team. AM is a volunteer who undertook literature reviews to
inform protocol development and contributed to initial drafts of manuscript
sections. All authors have been involved in the drafting and revision of the
manuscript. All have read and approved the final manuscript. Authorship for
any further publications resulting from this trial will be agreed by all co-
applicants as per the dissemination plan and will be based on substantive
contribution to the research described in each manuscript. No professional
writers will be used in any publications.
Funding
This trial was funded through a grant awarded by the UK autism research
charity Autistica following an open funding call focussed on mental health.
Autistica were not involved in the study design and collection, analysis,
interpretation of data, or writing of the manuscript. Autistica is an NIHR
partner organisation and thus the PAT-A© trial has been adopted to the
NIHR portfolio of studies that receive support from the Clinical Research
Network. The PAT-A© trial is part of the Autism Spectrum Adulthood and
Ageing Research Programme at Newcastle University (https://research.ncl.ac.
uk/adultautismspectrum/).
Availability of data and materials
Anonymised datasets used and/or analysed may be available from the
corresponding author upon reasonable request. If the research data shows
acceptability and efficacy, the PAT-A© treatment manuals will be available
from the authors in the future. The final trial dataset (anonymised) will
otherwise only be accessible by the Trial Management Team led by the co-
lead investigators (JP and JR).
Ethics approval and consent to participate
This study was approved by the NHS Health Research Authority and Wales
Research Ethics Committee (Wales REC 5; REC Reference: 18/WA/0014; IRAS
Project ID: 235805). Any significant changes to the protocol will be
submitted in writing to the sponsor, REC and Health Research Authority
(HRA). Written informed consent will be obtained from all individuals by the
RA before initiation of study procedures.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Author details
1Population Health Sciences Institute, Newcastle University, Newcastle upon
Tyne, UK. 2Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust,
Newcastle upon Tyne, UK. 3School of Psychology, Newcastle University,
Newcastle upon Tyne, UK.
Received: 15 October 2019 Accepted: 11 February 2020
References
1. Association AP. Diagnostic and Statistical Manual of Mental Disorders. 5th
ed. Washington: APA; 2013.
2. Matson JL, Williams LW. Differential diagnosis and comorbidity:
distinguishing autism from other mental health issues. Neuropsychiatry.
2013;3(2):233–43.
3. Croen LA, Zerbo O, Qian Y, Massolo ML, Rich S, Sidney S, et al. The health
status of adults on the autism spectrum. Autism. 2015;19(7):814–23.
4. Lugnegård T, Hallerbäck MU, Gillberg C. Psychiatric comorbidity in young
adults with a clinical diagnosis of Asperger syndrome. Res Dev Disabil. 2011;
32(5):1910–7.
5. Buck TR, Viskochil J, Farley M, Coon H, McMahon WM, Morgan J, et al.
Psychiatric comorbidity and medication use in adults with autism spectrum
disorder. J Autism Dev Disord. 2014;44(12):3063–71.
6. Joshi G, Wozniak J, Petty C, Martelon MK, Fried R, Bolfek A, et al. Psychiatric
comorbidity and functioning in a clinically referred population of adults
with autism spectrum disorders: a comparative study. J Autism Dev Disord.
2013;43(6):1314–25.
Parr et al. Trials          (2020) 21:265 Page 12 of 14
7. Kerns CM, Kendall PC, Berry L, Souders MC, Franklin ME, Schultz RT, et al.
Traditional and atypical presentations of anxiety in youth with autism
spectrum disorder. J Autism Dev Disord. 2014;44(11):2851–61.
8. World Health Organization. International Classification of Functioning,
Disability and Health (ICF). Geneva: World Health Organization; 2001.
9. de Schipper E, Mahdi S, de Vries P, Granlund M, Holtmann M, Karande S,
et al. Functioning and disability in autism spectrum disorder: a worldwide
survey of experts. Autism Res. 2016;9(9):959–69.
10. Mason D, Mackintosh J, McConachie H, Rodgers J, Finch T, Parr JR. Quality
of life for older autistic people: the impact of mental health difficulties. Res
Autism Spectr Disord. 2019;63:13–22.
11. Griffiths S, Allison C, Kenny R, Holt R, Smith P, Baron-Cohen S. The
Vulnerability Experiences Quotient (VEQ): a study of vulnerability, mental
health and life satisfaction in autistic adults. Autism Res. 2019;12(10):1516–28.
12. Lipinski S, Blanke ES, Suenkel U, Dziobek I. Outpatient psychotherapy for
adults with high-functioning autism spectrum condition: utilization,
treatment satisfaction, and preferred modifications. J Autism Dev Disord.
2018;49(3):1154–1168.
13. Hallett SC, Crompton CJ. Too complicated to treat? Autistic people seeking
mental health support in Scotland. Edinburgh: AMASE; 2018.
14. Camm-Crosbie L, Bradley L, Shaw R, Baron-Cohen S, Cassidy S. ‘People like
me don’t get support’: autistic adults’ experiences of support and treatment
for mental health difficulties, self-injury and suicidality. Autism. 0(0):
1362361318816053.
15. National Institute for Health and Care Excellence. Common mental health
problems: identification and pathways to care. Clinical guideline [CG123]. 2011.
16. National Institute for Health and Care Excellence. Generalised anxiety
disorder and panic disorder in adults: management: Clinical guideline
[CG113]. 2011.
17. Spain D, Sin J, Chalder T, Murphy D, Happé F. Cognitive behaviour therapy
for adults with autism spectrum disorders and psychiatric co-morbidity: a
review. Res Autism Spectr Disord. 2015;9:151–62.
18. Brunsdon VEA, Happé F. Exploring the ‘fractionation’ of autism at the
cognitive level. Autism. 2013;18(1):17–30.
19. Harris PL, Leevers HJ. Pretending, imagery and self-awareness in autism.
Understanding other minds: perspectives from developmental cognitive
neuroscience. 2nd ed. New York: Oxford University Press; 2000. p. 182–202.
20. Gaus VL. Adult Asperger syndrome and the utility of cognitive-behavioral
therapy. J Contemp Psychother. 2011;41(1):47–56.
21. Mason D, Ingham B, Urbanowicz A, Michael C, Birtles H, Woodbury-Smith M,
et al. A systematic review of what barriers and facilitators prevent and
enable physical healthcare services access for autistic adults. J Autism Dev
Disord. 2019;49(8):3387–3400.
22. South M, Rodgers J. Sensory, emotional and cognitive contributions to
anxiety in autism spectrum disorders. Front Hum Neurosci. 2017;11:20.
23. Trembath D, Germano C, Johanson G, Dissanayake C. The experience of
anxiety in young adults with autism spectrum disorders. Focus Autism
Other Dev Disabil. 2012;27(4):213–24.
24. Simon Wallace JPAH. One in a hundred: putting families at the heart of
autism research. London: Autistica; 2013.
25. James Lind Alliance. Autism Top Ten. 2016.
26. Social Care LGaCPD, Department of Health. Think Autism: Fulfilling and
Rewarding Lives, the strategy for adults with autism in England: an update.
London: Department of Health; 2014.
27. National Institute for Health and Care Excellence. Autism spectrum disorder
in adults: diagnosis and management. Clinical guideline [CG142]. 2012.
28. White SW, Simmons GL, Gotham KO, Conner CM, Smith IC, Beck KB, et al.
Psychosocial treatments targeting anxiety and depression in adolescents
and adults on the autism spectrum: review of the latest research and
recommended future directions. Curr Psychiatry Rep. 2018;20(10):82.
29. Cardaciotto L, Herbert JD. Cognitive behavior therapy for social anxiety
disorder in the context of Asperger's syndrome: a single-subject report.
Cogn Behav Pract. 2004;11(1):75–81.
30. Turner MA, Hammond N. Cognitive behavioural therapy in the treatment of
social skills deficits and social phobia in a man with an autism spectrum
disorder: a single-case study. Cogn Behav Ther. 2016;9:e3.
31. Weiss JA, Lunsky Y. Group cognitive behaviour therapy for adults with
Asperger syndrome and anxiety or mood disorder: a case series. Clin
Psychol Psychother. 2010;17(5):438–46.
32. Langdon PE, Murphy GH, Shepstone L, Wilson ECF, Fowler D, Heavens D,
et al. The People with Asperger Syndrome and Anxiety disorders (PAsSA)
trial: a pilot multicentre, single-blind randomised trial of group cognitive-
behavioural therapy. BJPsych Open. 2018;2(2):179–86.
33. Maskey M, Rodgers J, Ingham B, Freeston M, Evans G, Labus M, Parr JR.
Using virtual reality environments to augment cognitive behavioural
therapy for fears and phobias in autistic adults. Autism Adulthood.
2019;1(2):134–45.
34. Kiep M, Spek AA, Hoeben L. Mindfulness-based therapy in adults with an
autism spectrum disorder: do treatment effects last? Mindfulness.
2015;6(3):637–44.
35. Sizoo BB, Kuiper E. Cognitive behavioural therapy and mindfulness based
stress reduction may be equally effective in reducing anxiety and
depression in adults with autism spectrum disorders. Res Dev Disabil.
2017;64:47–55.
36. Boulter C, Freeston M, South M, Rodgers J. Intolerance of uncertainty as a
framework for understanding anxiety in children and adolescents with
autism spectrum disorders. J Autism Dev Disord. 2014;44(6):1391–402.
37. Chamberlain PD, Rodgers J, Crowley MJ, White SE, Freeston MH, South M. A
potentiated startle study of uncertainty and contextual anxiety in
adolescents diagnosed with autism spectrum disorder. Mol Autism.
2013;4(1):31.
38. Wigham S, Rodgers J, South M, McConachie H, Freeston M. The interplay
between sensory processing abnormalities, intolerance of uncertainty,
anxiety and restricted and repetitive behaviours in autism spectrum
disorder. J Autism Dev Disord. 2015;45(4):943–52.
39. Keefer A, Kreiser NL, Singh V, Blakeley-Smith A, Duncan A, Johnson C, et al.
Intolerance of uncertainty predicts anxiety outcomes following CBT in
youth with ASD. J Autism Dev Disord. 2017;47(12):3949–58.
40. Rodgers J, Herrema R, Honey E, Freeston M. Towards a treatment for
intolerance of uncertainty for autistic adults: a single case experimental
design study. J Autism Dev Disord. 2018;48(8):2832–45.
41. Lancaster GA, Dodd S, Williamson PR. Design and analysis of pilot studies:
recommendations for good practice. J Eval Clin Pract. 2004;10(2):307–12.
42. Gu J, Strauss C, Bond R, Cavanagh K. How do mindfulness-based cognitive
therapy and mindfulness-based stress reduction improve mental health and
wellbeing? A systematic review and meta-analysis of mediation studies. Clin
Psychol Rev. 2015;37:1–12.
43. Conner CM, White SW. Brief report: feasibility and preliminary efficacy of
individual mindfulness therapy for adults with autism spectrum disorder. J
Autism Dev Disord. 2018;48(1):290–300.
44. Rodgers J, Hodgson A, Shields K, Wright C, Honey E, Freeston M. Towards a
treatment for intolerance of uncertainty in young people with autism
spectrum disorder: development of the Coping with Uncertainty in
Everyday Situations (CUES©) programme. J Autism Dev Disord. 2017;47(12):
3959–66.
45. National Institute for Health and Care Excellence. Social anxiety disorder:
recognition, assessment and treatment. Clinical Guideline [CG159]. 2013.
46. Maskey M, Lowry J, Rodgers J, McConachie H, Parr JR. Reducing specific
phobia/fear in young people with Autism Spectrum Disorders (ASDs)
through a virtual reality environment intervention. PLoS One. 2014;9(7):
e100374.
47. Maskey M, McConachie H, Rodgers J, Grahame V, Maxwell J, Tavernor L,
et al. An intervention for fears and phobias in young people with autism
spectrum disorders using flat screen computer-delivered virtual reality and
cognitive behaviour therapy. Res Autism Spectr Disord. 2019;59:58–67.
48. Brown TA, Barlow DH. Anxiety and Related Disorders Interview Schedule for
DSM-5 (ADIS-5L)-lifetime version: client interview schedule 5-copy set
(treatments that work); 2014.
49. Arnold LE, Vitiello B, McDougle C, Scahill L, Shah B, Gonzalez NM, et al.
Parent-defined target symptoms respond to risperidone in RUPP autism
study: customer approach to clinical trials. J Am Acad Child Adolesc
Psychiatry. 2003;42(12):1443–50.
50. Maskey M, Rodgers J, Grahame V, Glod M, Honey E, Kinnear J, et al. A
randomised controlled feasibility trial of immersive virtual reality treatment
with cognitive behaviour therapy for specific phobias in young people with
autism spectrum disorder. J Autism Dev Disord. 2019;49(5):1912–27.
51. Maskey M, Rodgers J, Ingham B, Freeston M, Evans G, Labus M, et al. Using
virtual reality environments to augment cognitive behavioral therapy for
fears and phobias in autistic adults. Autism Adulthood. 2019;1(2):134–45.
52. McConachie H, McLaughlin E, Grahame V, Taylor H, Honey E, Tavernor L,
et al. Group therapy for anxiety in children with autism spectrum disorder.
Autism. 2014;18(6):723–32.
Parr et al. Trials          (2020) 21:265 Page 13 of 14
53. Gruber JNCCP. Social Responsiveness Scale-Second Edition (SRS-2). Torrance:
Western Psychological Services; 2012.
54. Mandell DS, Lawer LJ, Branch K, Brodkin ES, Healey K, Witalec R, et al.
Prevalence and correlates of autism in a state psychiatric hospital. Autism.
2012;16(6):557–67.
55. Rodgers J, Farquhar K, Mason D, Brice S, Wigham S, Ingham B, et al.
Development and initial evaluation of the Anxiety Scale for Autism–Adult
(ASA-A). https://doi.org/10.1089/aut.2019.0044.
56. Rodgers J, Wigham S, McConachie H, Freeston M, Honey E, Parr JR.
Development of the Anxiety SCale for children with Autism Spectrum
Disorder (ASC-ASD). Autism Res. 2016;9(11):1205–15.
57. Uljarević M, Richdale AL, McConachie H, Hedley D, Cai RY, Merrick H, et al.
The Hospital Anxiety and Depression Scale: factor structure and
psychometric properties in older adolescents and young adults with autism
spectrum disorder. Autism Res. 2018;11(2):258–69.
58. The WHOQOL Group. Development of the World Health Organization
WHOQOL-BREF Quality of Life Assessment. Psychol Med. 1998;28(3):551–8.
59. Ayres M, Parr JR, Rodgers J, Mason D, Avery L, Flynn D. A systematic review
of quality of life of adults on the autism spectrum. Autism. 2018;22(7):774–83.
60. Power MJ, Green AM, The W-DG. Development of the WHOQOL disabilities
module. Qual Life Res. 2010;19(4):571–84.
61. McConachie H, Mason D, Parr JR, Garland D, Wilson C, Rodgers J. Enhancing
the validity of a quality of life measure for autistic people. J Autism Dev
Disord. 2018;48(5):1596–611.
62. Herdman M, Gudex C, Lloyd A, Janssen MF, Kind P, Parkin D, et al.
Development and preliminary testing of the new five-level version of EQ-5D
(EQ-5D-5L). Qual Life Res. 2011;20(10):1727–36.
63. Janssen MF, Pickard AS, Golicki D, Gudex C, Niewada M, Scalone L, et al.
Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across
eight patient groups: a multi-country study. Qual Life Res. 2013;22(7):1717–27.
64. Bagby RM, Parker JDA, Taylor GJ. The twenty-item Toronto Alexithymia
Scale—I. Item selection and cross-validation of the factor structure. J
Psychosom Res. 1994;38(1):23–32.
65. Berthoz S, Hill EL. The validity of using self-reports to assess emotion
regulation abilities in adults with autism spectrum disorder. Eur Psychiatry.
2005;20(3):291–8.
66. Bell ML, Fairclough DL, Fiero MH, Butow PN. Handling missing items in the
Hospital Anxiety and Depression Scale (HADS): a simulation study. BMC Res
Notes. 2016;9(1):479.
67. Linden M. How to define, find and classify side effects in psychotherapy:
from unwanted events to adverse treatment reactions. Clin Psychol
Psychother. 2013;20(4):286–96.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Parr et al. Trials          (2020) 21:265 Page 14 of 14
